Perspective Therapeutics, Inc.
CATXNYSEAMERICANHealthcareMedical Devices
As of Oct 26, 2026 close
- Market cap
- $145.99M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $1.96$6.16
- Volume (live)
- -
- Avg. volume (3M)
- 2.57M
Perspective Therapeutics (CATX) Stock Price & Financial Analysis
Perspective Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $1.12 - $1.58 |
|---|---|
| 52-Week High | $6.16 |
| 52-Week Low | $1.96 |
| Open | $1.58 |
| Volume (last close) | 9.62M |
| Average Volume (3M) | 2.57M |
| Revenue (TTM) | 366.00K |
|---|---|
| Net Income (TTM) | -116.43M |
| Free Cash Flow (TTM) | -121.19M |
| EPS (TTM) | −$1.25 |
| Profit Margin | -31812.57% |
| Operating Margin | -34216.39% |
| Return on Equity (ROE) | -35.95% |
| Debt to Equity | 0.00 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 145.99M |
|---|---|
| Shares Outstanding | 120.65M |
| Price to Sales (P/S) | 398.87 |
| Price to Book (P/B) | 0.45 |
| EV/EBITDA | -2.00 |
| 50-Day MA | $2.84 |
|---|---|
| 200-Day MA | $3.59 |
| 1-Year Change | −21.53% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Perspective Therapeutics at a Glance
As of the Oct 26, 2026 close, Perspective Therapeutics (CATX) has a market capitalization of $145.99M. The stock trades at 398.9× sales. Over the trailing twelve months it lost $116.43M on revenue of $366.00K and burned $121.19M of free cash flow. Revenue fell 64.4% year over year.
As of its latest reported balance sheet, it holds $48.49M in cash and securities against $1.60M of debt, a net cash position of $46.89M.
Perspective Therapeutics does not currently pay a dividend.
The share price is down 21.5% over the past year. At $1.21 (the Oct 26, 2026 close) it sits near the bottom of its 52-week range of $1.96 to $6.16, below its 200-day moving average of $3.59.
Based on 16 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $12.00, 891.7% above the Oct 26, 2026 close.
Frequently Asked Questions About Perspective Therapeutics
What is the current stock price for CATX?
As of the Oct 26, 2026 close, CATX stock trades at $1.21. The 52-week range is $1.96–$6.16, with a day range of $1.11–$1.58.
What is the P/E ratio for CATX?
The P/E ratio (Price-to-Earnings) for CATX is shown in the Key Statistics section. This valuation metric helps compare Perspective Therapeutics, Inc. to industry peers.
Does CATX pay dividends?
Perspective Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for CATX?
Based on ratings from 16 professional analysts over the last 90 days, the consensus for CATX is Buy. The average 12-month price target is $12.00, a 891.7% upside from the Oct 26, 2026 close of $1.21.
What is the market cap of CATX?
As of the Oct 26, 2026 close, Perspective Therapeutics's market capitalization is $146.0M, classifying it as a micro-cap company. Perspective Therapeutics operates in the Healthcare sector within the Medical Devices industry.